The release of soluble forms of TRAIL and DR5 by neutrophils of oral cavity cancer patients

Folia Histochemica et Cytobiologica

Volumn 46, Issue 2, 2008, Pages 177-183

  Jablonska, Ewa ^a   Jablonski, Jakub ^a   Marcinczyk, Magdalena ^a   Grabowska, Zyta ^a   Piotrowski, Leszek ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

(TNF) related apoptosis inducing ligand; DR5 receptor; Neutrophils; Oral cavity cancer; Peripheral blood mononuclear cells

Indexed keywords

CYTOPLASM PROTEIN; DEATH RECEPTOR 5; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; CELL EXTRACT; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR;

ADULT; ARTICLE; CANCER CELL CULTURE; CANCER STAGING; CELL ISOLATION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; MOUTH CANCER; NEUTROPHIL; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN SECRETION; SQUAMOUS CELL CARCINOMA; WESTERN BLOTTING; BLOOD; CASE CONTROL STUDY; METABOLISM; MIDDLE AGED; MONONUCLEAR CELL; MOUTH TUMOR; PATHOLOGY; SECRETION; SOLUBILITY;

ADULT; BLOTTING, WESTERN; CASE-CONTROL STUDIES; CELL EXTRACTS; HUMANS; LEUKOCYTES, MONONUCLEAR; MIDDLE AGED; MOUTH NEOPLASMS; NEOPLASM STAGING; NEUTROPHILS; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; SOLUBILITY; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 48449105009     PISSN: 02398508     EISSN: None     Source Type: Journal    
DOI: 10.2478/v10042-008-0027-2     Document Type: Article

References (24)

1. Cassatella MA. The production of cytokines by polymorphonuclear neutrophils. Immunol Today. 1995;16:21-6.
2. Di Carlo E, Forni G, Lollini P, Colombo MP, Modesti A, Musiani P. The intriguing role of polymorphonuclear neutrophils in antitumor reactions. Blood. 2001;97:339-345.
3. Szymkowiak ChH, Csernok E, Reinhold D, Bank U, Gross WL, Kekow J. Neutrophils synthesize and activate TGFβ2. Cytokine. 2000;12:397-400.
4. Kamohara H, Matsuyama W, Shimozato O, Abe K, Galligan C, Hashimoto S, Matsushima K, Yoshimura T. Regulation of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) and TRAIL receptor expression in human neutrophils. Immunology. 2004;111:186-194.
5. Scapini P, Nardelli B, Nadali G, Calzetti F, Pizzolo G, Montecucco C, Cassatella MA. G-CSF-stimulated neutrophils are a prominent source of functional BLyS. J Exp Med. 2003;197: 297-302.
6. Tecchio C, Huber V, Scapini P, Calzetti F, Margotto D, Todeschini G, et al. IFNα-stimulated neutrophils and monocytes release a soluble form of TNF-related apoptosis-inducing ligand (TRAIL/Apo-2 ligand) displaying apoptotic activity on leukemic cells. Blood. 2004; 103:3837-3844.
7. Ehrlich S, Infante-Duarte C, Seeger B, Zipp F. Regulation of soluble and surface-bound TRAIL in human T cells, B cells, and monocytes. Cytokine. 2003;24:244-253.
8. Almasan A, Ashkenazi A. Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy. Cytokine Growth Factor Rev. 2003;14:337-348.
9. Griffith TS, Lynch DH. TRAIL: a molecule with multiple receptors and control mechanisms. Curr Opin Immunol. 1998;10:559-563.
10. MacFarlane M. TRAIL-induced signalling and apoptosis. Toxicol Lett. 2003;139:89-97.
11. Emery JG, McDonnell P, Burke MB, Deen KC, Lyn S, Silverman C, et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem. 1998;273:14363-14367.
12. Lee HW, Lee SH, Lee HW, Ryu YW, Kwon MH, Kim YS Himomeric and heteromeric interactions of the extracellular domains of death receptors and death decoy receptors. Biochem Biophys Res Com. 2005;330:1205-1212.
13. Miyashita T, Kawakami A, Kanshima T, Yamasaki S, Tamai M, Tanak A, et al.. Osteoprotegerin (OPG) acts as an endogenous decoy receptor in tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis of fibroblast-like synovial cells. Clin Exp Immuno. 2004,137:430-436.
14. Liang X, Liu Y, Zhang Q, Gao L, Han L, Ma Ch, Zhang L, Chen YH, Sun W. Hepatitis B virus sensitizes hepatocytes to TRAIL-induced apoptosis through Bax. J Immuno. 2007;178: 503-510.
15. Younes A, Kadin ME. Emerging applications of the tumor necrosis factor family of ligands and receptors in cancer therapy. J Clin Oncol. 2003;21:3526-3534.
16. Teng MS, Brandwein-Gensler MS, Teixeira MS, Martignetti JA, Duffey DC. A study of TRAIL receptors in squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg. 2005;131:407-412.
17. Sobin LH, Wittekind C. UICC TNM classification of malignant tumours, 5th ed. Berlin, Springer 1997.
18. Koga Y, Matsuzaki A, Suminoe A, Hattori H, Hara T. Neutrophil-derived TNF-related apoptosis-inducing ligand (TRAIL): a novel mechanism of antitumor effect by neutrophils. Cancer Res. 2004;64:1037-1043.
19. Stoppacciaro A, Melani C, Parenza M, Mastracchio A, Bassi C, et al. Regression of an established tumor genetically modified to release granulocyte colony-stimulating factor requires granulocyte - T cell cooperation and T cell - produced interferon gamma. J Exp Med. 1993;178:151-161.
20. Nagaraj NS, Vigneswaran N, Zacharias W. Cathepsin B mediates TRAIL-induced apoptosis in oral cancer cells. J Cancer Res Clin Oncol. 2006;132:171-183.
21. Secchiero P, Corallini F, Jasio MG, Gonelli A, Barbotto E, Zauli G. TRAIL counteracts the proadhesive activity of inflammatory cytokinez In endothelial cells by down-modulating CCL8 and CXCL10 chemokine expression and release. Blood. 2005;105:3413-3419.
22. Cantarella G, Risuglia N, Dell'eva R, Lempereur L, Albini A, Pennisi G, Scoto GM, Noonan DN, Bernardini R. TRAIL inhibits angiogenesis stimulated by VEGF expression in human glioblastoma cells. British J Can. 2006;94:1428-1435.
23. Jablonska E, Puzewska W, Grabowska Z, Jablonski J, Talarek L. VEGF, IL-18 and NO production by neutrophils and their serum levels In patients with oral cavity cancer. Cytokine. 2005;30:93-99.
24. Jablonska E, Kiluk M, Piotrowski L, Grabowska Z, Markiewicz W, Jablonski J. Tumor necrosis factor-alpha and soluble tumor necrosis factor receptors In the culture supernatants of polymorphonuclear cells and peripheral blond mononuclear cells from cancer patients. Eur Cytokine Netw. 1998;9:155-159.